Compare · INFU vs RMD
INFU vs RMD
Side-by-side comparison of InfuSystems Holdings Inc. (INFU) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INFU and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $26.52B, about 148.0x INFU ($179.2M).
- Over the past year, INFU is up 47.1% and RMD is down 25.9% - INFU leads by 73.0 points.
- INFU has been more active in the news (22 items in the past 4 weeks vs 6 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 3 for INFU).
- Company
- InfuSystems Holdings Inc.
- ResMed Inc.
- Price
- $8.93+0.45%
- $182.95-1.89%
- Market cap
- $179.2M
- $26.52B
- 1M return
- -13.89%
- -10.77%
- 1Y return
- +47.12%
- -25.93%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 22
- 6
- Recent ratings
- 3
- 25
InfuSystems Holdings Inc.
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) Services. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest INFU
- Executive VP and CFO Steele Barry G converted options into 16,226 shares, covered exercise/tax liability with 16,372 shares and was granted 21,323 shares, increasing direct ownership by 22% to 117,767 units (SEC Form 4)
- EVP-Chief HR Officer Funke Jerod was granted 14,570 shares, converted options into 5,183 shares and covered exercise/tax liability with 8,761 shares, increasing direct ownership by 59% to 29,654 units (SEC Form 4)
- President and CEO Lachance Carrie converted options into 19,350 shares, covered exercise/tax liability with 12,937 shares and was granted 21,855 shares, increasing direct ownership by 12% to 266,391 units (SEC Form 4)
- Executive VP and CIO Chupa Addam was granted 12,184 shares, converted options into 9,822 shares and covered exercise/tax liability with 8,056 shares, increasing direct ownership by 30% to 61,160 units (SEC Form 4)
- InfuSystems Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- InfuSystem Announces $20 Million Stock Repurchase Program
- SEC Form S-8 filed by InfuSystems Holdings Inc.
- SEC Form 4 filed by Director Hundzinski Ronald T
- SEC Form 4 filed by Director Shuda Scott
- SEC Form 4 filed by Director Sviokla John J
Latest RMD
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.
- Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor